Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Diasome Pharmaceuticals
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
US FDA heard a predictably wide range of advice on the appropriate standards for approving biosimilar and interchangeable insulin during a public hearing on the topic. What is surprising is how few sponsors decided to speak out.
Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.
USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.
- Drug Delivery